Triggering Immune System Antibody Response to Viral & Bacterial Infections: A Theoretical Overview of an Emerging Medical Paradigm

Research Article

Abstract

This paper shall propose the gene therapy model for selective reprogramming of adaptive immune white blood cells, specifically B-cells and T-cells, to autonomously produce tailored pathogen neutralizing antibodies and memory responses against a wide range of pathogenic infections. Through utilizing recent advances in CRISPR-Cas9, synthetic viral vectors, epitope mapping, and in vivo B-cell reprogramming, the proposed method activates specific genomic loci which are associated with immunoglobulin expression for the selective targeting of common hard to cure or incurable viral and bacterial epitopes.
Through introducing through synthetic gene therapy introduction of genetic modifications to the antibody-producing lymphocytes of the immune system whilst sparing the innate immune systems first line of defense of the phagocytes like neutrophils and macrophages for instance, this new gene therapy technique enhances the hosts background general immune protection against viral and bacterial infections without compromising the immediate adaptability of the first-line immune defense mechanisms. This could potentially represent a paradigm shift milestone in prophylactic and therapeutic immunology for diseases such as influenza, HIV, RSV, COVID-19, MRSA, tuberculosis, and many more.